Skip to main content

Month: March 2024

Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Written by Customer Service on . Posted in Public Companies.

The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in CanadaRHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca.The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the launch of RHO Phyto Micro Drop 100, a 10% CBD (THC free), proprietary oral formulation in Canada. RHO Phyto Micro Drop 100, is designed to deliver enhanced absorption of cannabinoids through an inverted emulsion technology....

Continue reading

Alamos Gold Announces Friendly Acquisition of Argonaut Gold

Written by Customer Service on . Posted in Mergers And Acquisitions.

Unlocking Value Through the Creation of One of Canada’s Largest and Lowest Cost Gold Mines TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — Alamos Gold Inc. (“Alamos”) (TSX:AGI; NYSE:AGI) and Argonaut Gold Inc. (“Argonaut”) (TSX:AR) are pleased to announce that they have entered into a definitive agreement (the “Agreement”) whereby Alamos will acquire all of the issued and outstanding shares of Argonaut pursuant to a court approved plan of arrangement (the “Transaction”). As part of the Transaction, Alamos will acquire Argonaut’s Magino mine, located adjacent to its Island Gold mine in Ontario, Canada. The integration of the two operations is expected to create one of the largest and lowest cost gold mines in Canada. Through the use of shared infrastructure, Alamos expects to unlock significant value with immediate and long-term synergies...

Continue reading

Evaxion Announces Business Update and Full Year 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completion of initial phases of vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). MSD revealed as pharma partner for the EVX-B3 bacterial vaccine development program. Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA. Closing of $15 million Public Offering on February 5, 2024, with participation of MSD GHI. MSD GHI is now the single largest shareholder in Evaxion, with ownership of around...

Continue reading

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) and KEYTRUDA® in advanced head and neck cancer Strong safety profile of IL-12 fused antibody drug conjugate (PDS01ADC) demonstrated to date with data generated in >300 cancer patients; Versamune® HPV tested in >110 HNSCC patients Successful recent meeting with FDA provided clear guidance on trial design and regulatory pathway for pivotal randomized trial of triple combination in recurrent metastatic HPV-positive HNSCC Company to host conference call and webcast today at 8:00 AM ET PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology...

Continue reading

illumin Appoints Simon Cairns As Chief Executive Officer

Written by Customer Service on . Posted in Public Companies.

Tal Hayek to retire as illumin CEO to become Non-Executive Vice Chairman TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced the appointment of Simon Cairns as Chief Executive Officer, effective April 15th. Mr. Cairns is a highly experienced executive with a successful track record driving growth and performance in technology, services, and SaaS platform companies. With over 24 years of strategic leadership, finance, marketing, operations, and business and corporate development experience, Mr. Cairns joins illumin at a pivotal point in the Company’s growth.  Mr. Cairns most recently served as CEO of SPUD, western Canada’s largest...

Continue reading

R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report

Written by Customer Service on . Posted in Public Companies.

Report highlights R1’s commitment to corporate responsibility and sustainability across the company’s global footprint MURRAY, Utah, March 27, 2024 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, has released its 2023 Environmental, Social and Governance (ESG) report. The report details the company’s commitment to improving access to healthcare, bringing responsible global citizenship to life through its ESG program. R1 meets healthcare providers where they are on their revenue cycle journey and enables them to focus on what matters most – their patients, their employees and the health of their business. The company’s mission to make healthcare work better for all inspires R1’s efforts...

Continue reading

brooqLy Launches Operations in Sub-Saharan Africa with MrExportToAfrica

Written by Customer Service on . Posted in Public Companies.

brooqLy is a technology company that has developed an innovative platform for consumers, brands, and retail shops to connect and interact through a Social Networking experiencebrooqLy Launches Operations in Sub-Saharan Africa with MrExportToAfricabrooqLy is a technology company that has developed an innovative platform for consumers, brands, and retail shops to connect and interact through a Social Networking experiencePALOS HILLS, Ill., March 27, 2024 (GLOBE NEWSWIRE) — brooqLy, Inc. (OTC: BRQL), a technology company, today announced a partnership, with MrExportToAfrica, an admirable international consulting firm headquartered in Ndola, Zambia. This partnership represents brooqLy’s commitment to delivering its platform across all continents, leveraging the expertise and local knowledge provided...

Continue reading

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Written by Customer Service on . Posted in Public Companies.

– Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination – – Phase 1 portion of the Phase 1/2a trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IMM-6-415 and establish a candidate recommended Phase 2 dose (RP2D) – -Initial PK, PD and safety data expected in 2024 – CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF...

Continue reading

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Written by Customer Service on . Posted in Public Companies.

–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis (F4) is planned to initiate in the second quarter of 2024– SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) status to pegozafermin in patients with MASH. The PRIME status was supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin in patients with non-cirrhotic...

Continue reading

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccinationSpeaker: Dr. Sean TuckerDate: Wednesday, April 3, 2024 Time: 3:10 p.m. ETRoom: 207A About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.